Image source: Pixabay.com
Highlights
- EBOS Group is a diversified Australasian wholesaler, marketer and distributor of medical, pharmaceutical and healthcare products
- In 1HFY24, revenue of EBO went up by 7.1% YoY to AUD 6.6 billion and underlying profit after tax increased by 7.6% YoY to AUD 152.4 million
- Sybos Holdings Pte. Ltd. Has highest stake in EBO with a shareholding of nearly 18.70%
EBOS Group Limited (ASX: EBO) is an ASX-listed wholesaler, marketer, and distributor of medical, healthcare and pharmaceutical products. The company also owns, markets, and distributes an Australasian animal care brand.
In the first half of the financial year 2024 (1HFY24), EBO’s revenue surged by almost 7.1% YoY to AUD 6.6 billion, underlying EBITDA jumped 8.3% YoY to AUD 313.2 million and underlying profit after tax increased by 7.6% YoY to AUD 152.4 million.
The company announced a 7.5% YoY surge in its interim dividend on the back of healthy performance in 1HFY24.
During January 2024, the company witnessed positive trading conditions with increase in underlying EBITDA, with and without the Chemist warehouse contract.
Top 10 shareholders of EBO
The top 10 shareholders of EBO have around 33.19% shareholding in the firm, while top four have nearly 27.09% of the shareholding. Sybos Holdings Pte. Ltd. and Capital Research Global Investors have the maximum stakes in the firm with a shareholding of ~18.70% and ~3.76%, respectively.

Recent business update
Through an ASX update dated 4 June 2024, the company informed about the appointment of Andrew McLean as the chief executive officer (CEO) for Medical Technology, effective 5 August 2024. With this development, the existing CEO for Medical Technology, Matt Muscio will be transitioning to the position of non-executive director, beginning 1 January 2025. Further, the company informed that peter Williams will retire as a director after the 2024 annual general meeting.
Outlook
In FY24, the company expects to see organic earnings growth in animal care and healthcare segments, and capital expenditure is expected to rise, compared to FY23.
The focus is on growth investments, modernising facilities, expanding into new segments, pursuing strategic acquisitions to strengthen core businesses and explore related adjacencies in animal care and healthcare.
Share performance of EBO
EBO shares closed 0.817% lower at AUD 30.330 apiece on 12 June 2024 with a market cap of AUD 5.90 billion. In the last one year, EBO’s share price has increased by7.25%, while in the last three months, it has decreased by 12.09%.
The 52-week high of EBO is AUD 35.800, recorded on 31 July 2023and 52-week low is AUD 30.180, recorded on 3 June 2024.

EBO Daily Technical Chart, Source: REFINITIV
Note 1: Past performance is neither an Indicator nor a guarantee of future performance.
Note 2: The reference date for all price data, and currency, is 12 June 2024. The reference data in this report has been partly sourced from REFINITIV.
Disclaimer:
This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.
Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.
Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.
The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.
The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.
Kalkine does not issue, sell or deal in any financial products.
This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.
To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.
Copyright 2026 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this Article, or its content, may be reproduced in any form without our prior consent.